dpp 4 inhibitor glp 1 agonist Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes Effect of DPP4 inhibition on

Many patients with obesity are now managing their condition with a primarily pharmacological approach

[DOI] [PubMed] [Google Scholar] 52.Edfalk S, Steneberg P, Edlund H (2008) Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion

All authors read and approved the final manuscript

Iepsen EW, Lundgren JR, Hartmann B et al (2015) GLP-1 receptor agonist treatment increases bone formation and prevents bone loss in weight-reduced obese women

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing

New study confirms GLP-1 medications are safe for mental health in diabetes